Taxotere has been approved by the FDA and is considered a standard treatment for patients
with lung cancer who have failed prior platinum-containing regimens. The main purpose of
this research study is to determine if Aptosyn, when given in combination with Taxotere,
will result in prolonged survival when compared to Taxotere alone.
This study will also help determine tumor response rates, and the safety profile of Aptosyn
in combination with Taxotere.
... Read More
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with
advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone
dosing compared to the once every 3 week dosing regimen in participants with metastatic
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin
(GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response
and safety between the two drug combinations for the treatment of advanced non-small cell
lung cancer (NSCLC).
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell
lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage
IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of
Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions
develop. This trial is seeking patients 18 years or older that have been diagnosed with
Stage IIIB or ... Read More
This is a randomized, open label, multicenter clinical trial to compare the efficacy and
safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and
dexamethasone versus Velcade, melphalan, and prednisone in patients with previously
untreated multiple myeloma not considered candidates for high-dose chemotherapy and
autologous stem cell transplantation.
This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed
plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based
Intensification with autologous stem cell (ASCT) is currently the most effective treatment
for subjects under 65 and the essential goal is to achieve complete response (CR) or very
good partial response (VGPR= greater than 90% reduction of monoclonal component). However,
only 50% of patients achieve this CR/VGPR even with tandem ASCT early in the course of
Optimization of the conditioning regimen could improve this CR/VGPR rate. The combinaison of
... Read More
The purpose of this trial is to study the safety of treating patients with multiple myeloma
and at least one bone lesion with zoledronic acid 4mg intravenously (IV) every 3 - 4 weeks
for 2 years. Patients will receive a zoledronic acid infusion for 15 minutes or 30 minutes.
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard
chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients
who have not yet received chemotherapy for their lung cancer.
LGL leukemia represents a rare subtype of chronic T or NK lymphoproliferative disorders. It
is an indolent disease, the main hematological or autoimmune complications lead to a
treatment in more than 60% of patients.
Investigators set up at the University Hospital of Rennes, a database of more than 300
patients with LGL leukemia from major French services that support this disease, and
published in 2010 the largest series of patients in the world (n = 229). ... Read More
This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus
placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy
The goal of the present study is to assess, through a randomized phase II trial, the
efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent,
ESA-resistant, IPSS low and intermediate-1 risk MDS patients without chromosome 5
Patients will receive either Lenalidomide alone or Lenalidomide and Epoetin beta for 4
months. Responders will be eligible for maintenance treatment with cycles identical to the
first ... Read More
The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have
hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic
chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral
satraplatin in this patient population.
This study will evaluate the effects of an investigational drug in combination with
chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will
measure the effects of this combination on progression of lung cancer, cancer response to
treatments, and development of cancer-related bone lesions.
The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy
in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in
study CC-4047-MM-003 (NCT01311687) and discontinued treatment with high-dose dexamethasone
due to disease progression.
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12
months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first
line treatment of metastatic colorectal cancer.